Ontology type: schema:ScholarlyArticle
2014-08
AUTHORSArun A. Azad, Emma K. Beardsley, Sebastian J. Hotte, Susan L. Ellard, Lawrence Klotz, Joseph Chin, Christian Kollmannsberger, Som D. Mukherjee, Kim N. Chi
ABSTRACTPURPOSE: To investigate the efficacy and safety of combining vandetanib, an orally available multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR), with bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: This was an open-label, randomized phase II multi-center study. Eligible patients had rising PSA on androgen deprivation therapy, minimal symptoms and were chemotherapy-naïve. Protocol therapy was either vandetanib 300 mg oral daily plus bicalutamide 50 mg oral daily (Arm A) or bicalutamide 50 mg oral daily alone (Arm B) with cross-over to vandetanib monotherapy at progression. The primary endpoint was PSA response (≥ 50 % decline from baseline). RESULTS: Thirty-nine patients were recruited, 19 in Arm A and 20 in Arm B. PSA response was comparable in Arm A and Arm B (18 vs. 19 %). Time to PSA progression was 3.16 months (95 % confidence interval (CI): 1.09, not reached (NR)) for Arm A and 3.09 months (95 % CI: 1.22, NR) for Arm B. Treatment discontinuation due to adverse events was more common in Arm A compared to Arm B (42 vs. 5 %; p = 0.019). Treatment with vandetanib was associated with a reduction in soluble VEGFR-2 levels after two cycles but an increase in plasma VEGF levels. CONCLUSION: The combination of vandetanib and bicalutamide was associated with considerable toxicity and did not have superior efficacy over bicalutamide alone. Further evaluation of this combination is not warranted in mCRPC. More... »
PAGES746-752
http://scigraph.springernature.com/pub.10.1007/s10637-014-0091-8
DOIhttp://dx.doi.org/10.1007/s10637-014-0091-8
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1008660056
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/24671507
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Anilides",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Combined Chemotherapy Protocols",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Nitriles",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Piperidines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prostate-Specific Antigen",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prostatic Neoplasms, Castration-Resistant",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Protein Kinase Inhibitors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Quinazolines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Tosyl Compounds",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Vascular Endothelial Growth Factor A",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Vascular Endothelial Growth Factor Receptor-2",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada"
],
"type": "Organization"
},
"familyName": "Azad",
"givenName": "Arun A.",
"id": "sg:person.0716150242.71",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716150242.71"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada"
],
"type": "Organization"
},
"familyName": "Beardsley",
"givenName": "Emma K.",
"id": "sg:person.0672204513.24",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672204513.24"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Juravinski Cancer Centre",
"id": "https://www.grid.ac/institutes/grid.477522.1",
"name": [
"Juravinski Cancer Centre, Hamilton, ON, Canada"
],
"type": "Organization"
},
"familyName": "Hotte",
"givenName": "Sebastian J.",
"id": "sg:person.0660714273.18",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660714273.18"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"British Columbia Cancer Agency, Centre for the Southern Interior, Kelowna, BC, Canada"
],
"type": "Organization"
},
"familyName": "Ellard",
"givenName": "Susan L.",
"id": "sg:person.01004224136.10",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004224136.10"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sunnybrook Health Science Centre",
"id": "https://www.grid.ac/institutes/grid.413104.3",
"name": [
"Sunnybrook Health Sciences Centre, Toronto, ON, Canada"
],
"type": "Organization"
},
"familyName": "Klotz",
"givenName": "Lawrence",
"id": "sg:person.010764321372.53",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010764321372.53"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "London Health Sciences Centre",
"id": "https://www.grid.ac/institutes/grid.412745.1",
"name": [
"London Health Sciences Centre, London, ON, Canada"
],
"type": "Organization"
},
"familyName": "Chin",
"givenName": "Joseph",
"id": "sg:person.01225732325.58",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225732325.58"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada"
],
"type": "Organization"
},
"familyName": "Kollmannsberger",
"givenName": "Christian",
"id": "sg:person.0660645031.33",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660645031.33"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Juravinski Cancer Centre",
"id": "https://www.grid.ac/institutes/grid.477522.1",
"name": [
"Juravinski Cancer Centre, Hamilton, ON, Canada"
],
"type": "Organization"
},
"familyName": "Mukherjee",
"givenName": "Som D.",
"id": "sg:person.01237110113.33",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237110113.33"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada",
"Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, V5Z 4E6, Vancouver, BC, Canada"
],
"type": "Organization"
},
"familyName": "Chi",
"givenName": "Kim N.",
"id": "sg:person.01142252161.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1200/jco.2010.28.5981",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1000100366"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2011.35.5040",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1007010954"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2012.45.0494",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1013364059"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2011.36.1709",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1014560769"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/1476-4598-12-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016568960",
"https://doi.org/10.1186/1476-4598-12-7"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/1078-0432.ccr-12-2353",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019084394"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0090-4295(01)01010-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019718764"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/00005392-200102000-00095",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019723635"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/00005392-200102000-00095",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019723635"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.urolonc.2010.09.018",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1025524434"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2011.39.4767",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031092562"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/coc.0b013e31818b946b",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1032193378"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/coc.0b013e31818b946b",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1032193378"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/coc.0b013e31818b946b",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1032193378"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/1078-0432.ccr-06-1895",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1033284252"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/annonc/mdm554",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035066248"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2005.02.2574",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035170611"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s1470-2045(13)70184-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037354085"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0022-5347(01)64039-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1041774655"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/ijc.20917",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042434637"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/ijc.20917",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042434637"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/ijc.20917",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042434637"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/ijc.20917",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042434637"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.clgc.2011.11.003",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1044121834"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1074/jbc.m802392200",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1047823885"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1089/cbr.2008.0588",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1059242943"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1074795197",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1075104066",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1075108930",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1075208258",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1082397609",
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.1997.15.8.2928",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1083129509"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1083347110",
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2011.29.15_suppl.4515",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1083947895"
],
"type": "CreativeWork"
}
],
"datePublished": "2014-08",
"datePublishedReg": "2014-08-01",
"description": "PURPOSE: To investigate the efficacy and safety of combining vandetanib, an orally available multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR), with bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).\nMETHODS: This was an open-label, randomized phase II multi-center study. Eligible patients had rising PSA on androgen deprivation therapy, minimal symptoms and were chemotherapy-na\u00efve. Protocol therapy was either vandetanib 300 mg oral daily plus bicalutamide 50 mg oral daily (Arm A) or bicalutamide 50 mg oral daily alone (Arm B) with cross-over to vandetanib monotherapy at progression. The primary endpoint was PSA response (\u2265 50 % decline from baseline).\nRESULTS: Thirty-nine patients were recruited, 19 in Arm A and 20 in Arm B. PSA response was comparable in Arm A and Arm B (18 vs. 19 %). Time to PSA progression was 3.16 months (95 % confidence interval (CI): 1.09, not reached (NR)) for Arm A and 3.09 months (95 % CI: 1.22, NR) for Arm B. Treatment discontinuation due to adverse events was more common in Arm A compared to Arm B (42 vs. 5 %; p\u2009=\u20090.019). Treatment with vandetanib was associated with a reduction in soluble VEGFR-2 levels after two cycles but an increase in plasma VEGF levels.\nCONCLUSION: The combination of vandetanib and bicalutamide was associated with considerable toxicity and did not have superior efficacy over bicalutamide alone. Further evaluation of this combination is not warranted in mCRPC.",
"genre": "research_article",
"id": "sg:pub.10.1007/s10637-014-0091-8",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1094201",
"issn": [
"0167-6997",
"1573-0646"
],
"name": "Investigational New Drugs",
"type": "Periodical"
},
{
"issueNumber": "4",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "32"
}
],
"name": "A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy na\u00efve castration-resistant prostate cancer",
"pagination": "746-752",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"29422a0bc6c42fbdb28138708ee4184e2fb4fdfaa79895e2ddb9e62d7dc92f8d"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"24671507"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"8309330"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s10637-014-0091-8"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1008660056"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s10637-014-0091-8",
"https://app.dimensions.ai/details/publication/pub.1008660056"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-10T18:20",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000510.jsonl",
"type": "ScholarlyArticle",
"url": "http://link.springer.com/10.1007%2Fs10637-014-0091-8"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-014-0091-8'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-014-0091-8'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-014-0091-8'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-014-0091-8'
This table displays all metadata directly associated to this object as RDF triples.
275 TRIPLES
21 PREDICATES
72 URIs
36 LITERALS
24 BLANK NODES